Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) had its price target lowered by investment analysts at UBS Group from $30.00 to $24.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price would indicate a potential upside of 220.00% from the stock's current price.
Several other equities research analysts have also commented on the stock. Morgan Stanley restated an "overweight" rating and set a $35.00 target price (down from $38.00) on shares of Cullinan Therapeutics in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $33.00 target price on shares of Cullinan Therapeutics in a research report on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cullinan Therapeutics has an average rating of "Buy" and an average target price of $32.00.
Get Our Latest Stock Analysis on CGEM
Cullinan Therapeutics Price Performance
NASDAQ CGEM traded up $0.26 on Monday, hitting $7.50. 440,232 shares of the company's stock were exchanged, compared to its average volume of 585,215. The firm's 50-day moving average price is $8.01 and its two-hundred day moving average price is $10.32. Cullinan Therapeutics has a fifty-two week low of $6.85 and a fifty-two week high of $24.99. The firm has a market cap of $442.61 million, a price-to-earnings ratio of -2.64 and a beta of -0.07.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. On average, research analysts predict that Cullinan Therapeutics will post -3.04 earnings per share for the current fiscal year.
Insider Transactions at Cullinan Therapeutics
In other Cullinan Therapeutics news, CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares in the company, valued at approximately $3,673,197.13. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jeffrey Alan Jones sold 4,895 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $41,754.35. Following the completion of the sale, the insider now directly owns 174,164 shares in the company, valued at $1,485,618.92. This trade represents a 2.73% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.16% of the company's stock.
Hedge Funds Weigh In On Cullinan Therapeutics
Several hedge funds have recently bought and sold shares of CGEM. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cullinan Therapeutics in the first quarter valued at $163,000. Tema Etfs LLC lifted its holdings in Cullinan Therapeutics by 37.7% in the 1st quarter. Tema Etfs LLC now owns 39,164 shares of the company's stock valued at $296,000 after purchasing an additional 10,731 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Cullinan Therapeutics during the 1st quarter worth about $518,000. AlphaQuest LLC purchased a new stake in shares of Cullinan Therapeutics during the first quarter worth about $190,000. Finally, EntryPoint Capital LLC raised its position in shares of Cullinan Therapeutics by 65.0% in the first quarter. EntryPoint Capital LLC now owns 24,190 shares of the company's stock valued at $183,000 after buying an additional 9,533 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More

Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.